Industry Focus

Industry Focus

By The Motley FoolBusinessNewsBusiness News
Download on the App Store

Industry Focus episodes

  • CG: Three Pitches and a Home Run

    “Pitch Week” continues on Industry Focus as our Foolish contributors share their takes on Under Armour, Dave & Buster’s, and Tractor Supply Co.

    Thanks to Harry’s for supporting the Motley Fool. Get your free trial set -- go to Harrys.com/fool.

    35 min
  • Financials: Pitch Perfect

    We kick off "Pitch Week" with a look at payment companies Mastercard and Square, and wrap the show with a breakdown of why Warren Buffett's Berkshire Hathaway has been such a good business to own.

    27 min
  • Financials: Pitch Perfect

    We kick off "Pitch Week" with a look at payment companies Mastercard and Square, and wrap the show with a breakdown of why Warren Buffett's Berkshire Hathaway has been such a good business to own.

    27 min
  • Tech: Netflix - Price Hikes & All-Time Highs

    Netflix got a nice bump after announcing price increases to several of its service tiers – what might the increases mean for the company’s top line and what should investors be paying attention to ahead of the company’s earnings report next week?

    28 min
  • Tech: Netflix - Price Hikes & All-Time Highs

    Netflix got a nice bump after announcing price increases to several of its service tiers – what might the increases mean for the company’s top line and what should investors be paying attention to ahead of the company’s earnings report next week?

    28 min
  • Healthcare: Mylan's Big Bet

    Mylan launches a generic "at-risk" and Flexion's big drug opportunity becomes clearer.

    Editor's note: Mylan's drug was mistakenly referred to in the episode as a biosimilar. Copaxone, however, was approved under an NDA, not a BLA, so Mylan's copycat is a generic, not a biosimilar.

    19 min
  • Healthcare: Mylan's Big Bet

    Mylan launches a generic "at-risk" and Flexion's big drug opportunity becomes clearer.

    Editor's note: Mylan's drug was mistakenly referred to in the episode as a biosimilar. Copaxone, however, was approved under an NDA, not a BLA, so Mylan's copycat is a generic, not a biosimilar.

    19 min

About Industry Focus

From the publisher's feed

Healthcare, technology, energy, consumer goods, and more. Every day, Motley Fool analysts break down a specific industry and the stocks making headlines. Questions? Comments? Email us at…